Takeda Pharmaceutical Company Limited (TAK) Q1 2026 Earnings Call Transcript
Takeda Pharmaceutical Company Limited (TAK) Q1 2026 Earnings Call July 30, 2026 6:00 AM EDT
Company Participants
Christopher David O’Reilly – Global Head of Investor Relations & Global Finance
Julie Kim – CEO, President & Director
Milano Furuta – CFO & Director
Andrew Plump – President of Research & Development and Representative Director
Conference Call Participants
Hidemaru Yamaguchi – Citigroup Inc., Research Division
Shinichiro Muraoka – Morgan Stanley, Research Division
Matsubara – Nomura Securities Co. Ltd., Research Division
Michael Nedelcovych – TD Cowen, Research Division
Miki Sogi – Bernstein Institutional Services LLC, Research Division
Stephen Barker – Jefferies LLC, Research Division
Presentation
Christopher David O’Reilly
Global Head of Investor Relations & Global Finance
[Interpreted] Thank you very much for joining us today despite a very busy schedule for the FY ’26 Q1 earnings announcement by Takeda. My name is O’Reilly, and I’m the Head of IR. I’ll be facilitating the discussion today. Thank you for this opportunity. And first of all, allow me to explain about the language setting. [Operator Instructions] Before starting, I’d like to remind everyone that we will be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results to differ materially are discussed in our most recent Form 20-F and in our other SEC filings.
Please also refer to the important notice on Page 2 of the presentation regarding forward-looking statements and our non-IFRS financial measures, which will be also discussed during this call. Definitions of our non-IFRS measures and reconciliations with comparable IFRS financial statements are introduced in the appendix of the presentation. Now we would like to start the presentation. We have President and CEO, Julie Kim; Chief Financial Officer, Milano Furuta; and President, R&D, Andy Plump. They will do the presentation, which will be followed by the Q&A session. We will
